Accessibility Menu
Genetic Technologies logo

Genetic Technologies(ASX) GTG

Market CapA$52.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-100%
5 YearN/A
1 Year-85%
1 Month-10%
A$0.04
+2.63%
+0.00Today
Genetic Technologies last closing stock price
MetricPriceDate
Last closeAUD 0.042024-10-15
Genetic Technologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5%AUD 0.042024-10-08
1 month-9.52%AUD 0.042024-09-13
3 month-25.49%AUD 0.052024-07-17
Year to date-71.85%AUD 0.142023-12-29
1 year-84.8%AUD 0.252023-10-16
3 year-94.57%AUD 0.702021-10-15
Since inception-99.81%AUD 20.731992-01-02

Genetic Technologies Financials at a Glance

Market Cap

A$52.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$13.70M

Net Income (TTM)

-A$22.39M

EPS (TTM)

A$0.00

P/E Ratio

0.00

Dividend

A$0.00

Beta (Volatility)

-0.05 (Low)

Price

A$0.04

Volume

0

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.04 - A$0.04

Estimated Earnings Date

Aug 27, 2026

GTG News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Genetic Technologies

Genetic Technologies Limited is an Australian molecular diagnostics company that specializes in predictive genetic testing and risk assessment tools. Founded in 1987, the company aims to empower healthcare professionals globally to manage patient health proactively.

Products and Services
  • BREVAGenplus, a test for assessing non-hereditary breast cancer risk
  • GeneType for Colorectal Cancer and GeneType for Breast Cancer
  • Expanding genetic testing solutions across various medical and research applications
Growth Outlook
  • Recent partnerships with leading research institutions enhance product development
  • Expansion into new markets across the Americas, Europe, and Asia Pacific
  • Ongoing development of tests for ovarian cancer, prostate cancer, and more
Financial Highlights
  • Recent quarterly revenue of AUD 413,948, showing potential for growth
  • Trailing twelve months (TTM) gross profit margin at 50.94%, indicating strong product demand
  • Cash and cash equivalents of AUD 1,012,942, providing operational liquidity
Genetic Technologies Limited operates through two divisions: EasyDNA and GeneType/Corporate. The company is recognized for its innovative approach to genetic testing, particularly in cancer risk assessment. The BREVAGenplus test is a notable product that has gained traction among healthcare providers, including obstetricians and breast health specialists. The growth outlook for Genetic Technologies is promising, bolstered by strategic partnerships with prestigious institutions such as the University of Melbourne and Memorial Sloan Kettering. These collaborations are expected to enhance the company's research capabilities and accelerate the development of new testing solutions. Financially, the company has shown resilience, with a recent quarterly revenue of AUD 413,948, reflecting its ability to generate income despite challenges. The gross profit margin of 50.94% indicates a solid demand for its products, while the cash position of over AUD 1 million provides a buffer for ongoing operations and potential investments in growth initiatives. Overall, Genetic Technologies Limited presents a compelling opportunity for investors interested in the healthcare and diagnostics sector, particularly in the rapidly evolving field of genetic testing.
AI Generated • Jul 29, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

58

CEO

Simon Morriss

Website

www.genetype.com

Headquarters

Fitzroy, VIC 3065, AU

GTG Financials

Key Financial Metrics (TTM)

Gross Margin

50.94%

Operating Margin

-159.30%

Net Income Margin

-156.78%

Return on Equity

-184.98%

Return on Capital

-451.29%

Return on Assets

-194.25%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$52.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.34B

Volume

0

Avg. Volume

0

Financials (TTM)

Gross Profit

A$5.24K

Operating Income

-A$14.02M

EBITDA

-A$17.46M

Operating Cash Flow

-A$13.11M

Capital Expenditure

-A$33.25K

Free Cash Flow

-A$12.14M

Cash & ST Invst.

A$1.01M

Total Debt

A$500.00K

Genetic Technologies Performance Analysis

Genetic Technologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 6,794,816N/A
20232023-06-30AUD 8,686,11827.8%
20242024-06-30AUD 7,664,784-11.8%
Genetic Technologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-06-309.1%
Q22023-12-31-12.7%
Q42024-06-3021.2%
Q22024-12-31-91.4%
Genetic Technologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.08N/A
20232023-06-30AUD -0.1250.6%
20242024-06-30AUD -0.09-21.6%
Genetic Technologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-06-30-15.2%
Q22023-12-3118.4%
Q42024-06-3029.2%
Q22024-12-3124.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2025YOY CHG

Revenue

A$413.95K

-90.0%

Gross Profit

A$413.95K

+126.8%

Gross Margin

100.00%

N/A

Market Cap

A$52.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$946.93K

N/A

Employees

55

N/A

Net Income

-A$4.09M

+25.2%

EBITDA

-A$1.33M

+73.7%

Quarterly Fundamentals

Name
Q2 2025YOY CHG

Total Cash

A$1.01M

-79.9%

Total Debt

A$500.00K

-18.4%

Accounts Receivable

A$145.24K

-95.0%

Inventory

A$0.00

-100.0%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$500.00K

+76.1%

Return on Assets

-1.94%

N/A

Return on Invested Capital

-6.13%

N/A

Free Cash Flow

-A$78.35K

+97.1%

Operating Cash Flow

-A$71.27K

+97.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EOF.AXEcofibre Limited
A$0.02+0.00%
CGB.AXCann Global Limited
A$0.02+0.00%
UBI.AXUniversal Biosensors, Inc.
A$0.01+0.00%
VTI.AXVisioneering Technologies, Inc.
A$0.07+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About GTG

What is the current price of Genetic Technologies?

Genetic Technologies is trading at A$0.04 per share.

What is the 52-week range for Genetic Technologies?

Over the past 52 weeks, Genetic Technologies has traded between A$0.04 and A$0.04.

How much debt does Genetic Technologies have?

As of the most recent reporting period, Genetic Technologies reported total debt of A$875.19K.

How much cash does Genetic Technologies have on hand?

Genetic Technologies reported A$1.02M in cash and cash equivalents in its most recent financial results.

What is Genetic Technologies’s dividend yield?

Genetic Technologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services